SU‐GG‐J‐145: Physics Support for Intraprostatic Treatment of Patients with Locally Recurrent Prostate Cancer with the PSA‐Activated Protoxin PRX302

Medicine & Life Sciences

• Biopsy 3%
• Brachytherapy 6%
• Cell Death 4%
• Cell Membrane 4%
• Clinical Trials 3%
• Clinical Trials, Phase I 6%
• Conflict of Interest 7%
• Denmark 6%
• Hawks 9%
• Injections 6%
• Ions 4%
• Maximum Tolerated Dose 6%
• Membranes 3%
• Needles 5%
• Peptides 3%
• Physics 56%
• Preliminary Data 6%
• Prostate 9%
• Prostatic Neoplasms 36%
• Protoporphyrinogen Oxidase 10%
• PRX302 100%
• Radiotherapy 3%
• Software 4%
• Therapeutics 7%
• Ultrasonics 5%